TYG100 utilizes proprietary S-TIR™ technology platform enabling specific B cell and T cell responses against tumor antigens TYG100 utilizes proprietary S-TIR™ technology platform enabling specific B cell and T cell responses against tumor antigens

Go here to read the rest:
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh